HENGRUI PHARMA(01276.HK)

Event Tracking

Jan9

JPMorgan Increases Holdings in Hengrui Medicine by 1,127,828 Shares

11:57

Hengrui Medicine's Famataseran Capsule Marketing Authorization Application Accepted by NMPA

11:11

Hengrui Medicine Receives Approval for Multiple Drugs Clinical Trials and Will Soon Start Clinical Trials

09:06

Hengrui's SHR-1701 Approved for Marketing, Becoming the First PD-L1/TGF- Antibody

05:39

Jan7

Hengrui Medicine's Subsidiary's Relavapup α Injection Approved for Market

10:07

Jan5

Hengrui Medicine Receives Approval From NMPA To Conduct Clinical Trials For HRS-4357 And HRS-5041

09:38

Schedules & Filings

Schedules

Filings

Oct27

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 8.119 B, Net Income 1.422 B, EPS 0.2131

Aug20

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 9.364 B, Net Income 2.82 B, EPS 0.4359

May23

IPO(CST)

Listing Price HKD 44.05

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change